Investors can capitalize on downside momentum by shorting Moderna (MRNA) toward a target of $100, while also targeting high-conviction short positions in Capricor Therapeutics (CAPR) down to $6.00 and SELLAS Life Sciences (SLS) due to high clinical trial failure risks.

For bullish healthcare plays, Spruce Biosciences (SPRB) offers strong upside potential following recent positive news catalysts, and Biohaven (BHVN) represents a high-conviction long-term hold driven by proven management execution.

In the semiconductor space, consider a long position in Broadcom (AVGO) to benefit from the growing enterprise shift toward custom artificial intelligence chip design.

Active traders should look to short or avoid speculative rallies in the Quantum Computing Sector, as recent price surges lack fundamental revenue backing.

Finally, steer clear of microcap Solana Meme Tokens, which carry severe risks of capital loss due to illiquid markets and high price manipulation.

Moderna (MRNA)

• The speaker maintains an active short position on the stock, viewing recent upside moves (trading around $143) as temporary rallies that are likely to fade.
  • Expressed the view that the company is fundamentally overvalued and discussed downside targeting around $100.
  • Questioned the commercial viability and efficacy expectations for broad mRNA pipeline expansions beyond early-stage trial settings.

Takeaways

• Consider a bearish bias or risk-managed short position on MRNA, watching for rallies to fade toward lower valuation support levels.

SELLAS Life Sciences Group (SLS)

• The speaker identified the stock as a high-conviction short opportunity.
  • Stated a belief that the company's lead AML (acute myeloid leukemia) asset will fail clinical expectations.
  • Stated an ultimate expectation that the stock is headed toward zero.

Takeaways

• High downside risk flagged for SLS based on clinical trial skepticism; analyst sentiment is aggressively bearish.

Capricor Therapeutics (CAPR)

• The speaker initiated a renewed short position ("round two") on the stock.
  • Stated that the stock exhibits temporary price resilience but forecasted a drop down to $6.00.

Takeaways

• Bearish outlook with a specific mentioned price target of $6.00 as upside momentum wanes.

Spruce Biosciences (SPRB)

• The speaker is currently long the stock following a recent press release catalyst.
  • Indicated strong confidence that the stock has substantial upside remaining and is not purely dependent on a single binary clinical outcome.

Takeaways

• Bullish sentiment on SPRB with expectations of continued upside momentum.

NVIDIA (NVDA)

• Traded slightly up ahead of major live earnings catalysts, with valuation noted around $5 trillion.
  • Viewed as trading at a relative discount based on current earnings power, but warned that earnings remain cyclical.
  • Highlighted potential risks around memory specifications on the upcoming Vera Rubin Ultra architecture and long-term competition from custom merchant silicon (such as OpenAI designing chips in-house).

Takeaways

• Mixed-to-cautious outlook into earnings; upside is supported by strong earnings multiples, but long-term risks include chip cycle peaks and custom silicon competition.

Broadcom (AVGO)

• Discussed as a key design partner for proprietary custom AI silicon initiatives (such as OpenAI's specialized chips).
  • Viewed as a potential long-term beneficiary of hyperscalers developing in-house chips to reduce dependence on off-the-shelf GPUs.

Takeaways

• Bullish long-term positioning for AVGO as enterprise demand shifts toward custom ASIC design and merchant silicon.

Biohaven (BHVN)

• The speaker expressed strong trust and a bullish stance on the Biohaven management team.
  • Praised the team's historical capital allocation track record and ability to compound capital for shareholders.

Takeaways

• Positive long-term outlook on BHVN based on confidence in management execution.

Quantum Computing Sector

• The speaker holds active short positions across quantum computing equities.
  • Viewed the recent active trading volume and price spikes in the sector as speculative rather than grounded in near-term fundamental revenue.

Takeaways

• Bearish stance on speculative quantum tech stocks; consider avoiding or shorting momentum-driven spikes in the sector.

Solana Meme Tokens (SOL)

• The speaker engaged in short-term speculative trading on decentralized token launchpads (e.g., Pump.fun), actively trading microcap tokens such as Dog with Helmet and Citrini.
  • Emphasized extreme risks including severe illiquidity (shallow liquidity pools where reported market caps do not reflect actual cash exit potential), front-running bots, and abrupt market dumps.

Takeaways

• Microcap meme coins represent extreme risk, low-liquidity speculation with high vulnerability to manipulation and capital loss. Traders are advised to size down significantly or avoid entirely.